TLPH

Talphera Inc. Common Stock (TLPH)

Stock · NASDAQ · Health Care

$1.09as of 10/16/2026

Price chart

Open in TradingView

Active signals

Support Reject25.6%200 SMA Touch0.0%
Resistance level
$1.18
Industry
Biotechnology: Pharmaceutical Preparations

TLPH Signal Track Record

How signals performed across all stocks →

What TLPH's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.

SignalTimesMedian 20-session returnHigher after 20 sessions
Volume Spike56-4.5%34%
Bollinger Band Breakout26-9.8%35%
Bollinger Band Breakdown170.0%47%
200-Day Moving Average TouchActive now110.0%45%
Any 20-session window (baseline)-3.3%42%

Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.

About TLPH

Talphera, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. The company's lead product candidate, Niyad, is a lyophilized formulation of nafamostat that acts as a regional anticoagulant for infusion into the extracorporeal circuit. It is also developing LTX-608, a lyophilized vial containing nafamostat for IV infusion for…

Sector
Health Care
Industry
Biotechnology: Pharmaceutical Preparations
Employees
12

Fundamentals

1-day range
$1.06$1.14
Market cap
$74.22M
P/E (trailing)
—
P/E (forward)
-4.84
EPS (trailing)
$-0.26
Dividend yield
—
Beta
0.76
Avg. volume
197.4K
52-week range
$0.6866$1.57
Next earnings: November 11, 2026 · EPS estimate $-0.05confirmed

How Talphera Inc. Common Stock Makes Money

Where the revenue actually goes — FY2025 annual results

market-wall.comTotalRevenue$28.0KSG&A$7.48M (26711%)R&D$6.03M (21546%)TLPH

Source: 10-K filed Mar 23, 2026 · via SEC EDGAR / Finnhub

Operating Income-$13.48M(-48157%)

Forecasts

4 analyst ratings

Buy 89%
Hold 11%
Sell 0%
1-year price forecast
High
$3.5
+222.6%
Median
$3
+176.5%
Low
$3
+176.5%

Talphera Inc. Common Stock Competitors

Chosen by industry and closest market cap.

  • TLPH
    Talphera Inc. Common Stock
    $1.08
    ▲ 0.93%
    Market cap $74.22MP/E —
    $0.6866$1.57
  • OSTX
    OS Therapies Incorporated Common Stock
    $1.32
    ▼ 6.38%
    Market cap $74.23MP/E —
    $1.15$2.25
  • ACET
    Adicet Bio Inc. Common Stock
    $4.57
    ▼ 11.09%
    Market cap $74.13MP/E —
    $4.8$17.04
  • SPRO
    Spero Therapeutics Inc. Common Stock
    $1.1
    ▼ 2.65%
    Market cap $73.53MP/E 8.91
    $1.08$3.08
  • NMAD
    Nomad Power Solutions Inc. Common Stock
    $3.88
    ▼ 5.13%
    Market cap $75.50MP/E —
    $3.12$7.7
  • GANX
    Gain Therapeutics Inc. Common Stock
    $1.26
    ▼ 5.26%
    Market cap $75.92MP/E —
    $1.3$4.34
  • ACRV
    Acrivon Therapeutics Inc. Common Stock
    $1.64
    ▼ 6.82%
    Market cap $72.33MP/E —
    $1.27$3.56

P/E shows — for peers not currently carrying a live signal of their own.

Latest news

Insider Activity

Insider Actions →
Acquired
250.6K
Disposed
4.5K

Institutional Ownership

March 31, 2026

Total shares held
21.85M
Total value held
$16.24M
Institutional holders
44
Top holders this quarter
  • Unknown4.66M
  • Unknown3.59M
  • Unknown3.49M
  • Unknown3.35M
  • Unknown1.31M
  • Unknown887.5K
  • Unknown590.5K
  • Unknown561.8K
  • Unknown467.2K
  • Unknown441.6K

See the full, filterable feed with live charts on the MarketWall dashboard.

We use analytics to understand how market-wall is used. No personal data is sold.